Key information

– Meeting date: November 18-19, 2021
– Location: Basel Universitätsspital (in person, covid certificate required)
– Payment information: – Click here –

Program

Thursday 18th of November 2021

Location: University Hospital, ZLF, “Kleiner Hörsaal”, ground floor, Hebelstrasse 20, 4031 Basel

13.30 – Session 1: ER+ Breast Cancer – Can we ERase them all ?  (Chair: Priska Auf der Mauer and Marcus Vetter)

• Basic: Steffi Öesterrich, University of Pittsburg: Estrogen Receptor Mutations – No one-size-fits-all.
  Anti-angiogenic cancer immunotherapy
• Clinic: Marcus Vetter, Canton Hospital Baselland: How to overcome endocrine resistance in ER+/HER- metastatic breast cancer
  
• Industry: Benjamin Peschke, AstraZeneca AG, Baar: OlympiA – New Option for gBRCAm HER2neg early breast cancer patients ?
  

15.15 – Break

15.45-16.15 – Speed posters: presentation of 10 posters

16.15 – Session 2: What are the news from the HER2 front (Chair: Nancy Hynes and Christoph Rochlitz)

• Basic: Manuel Valiente, Centro National de Investigaciones Oncológicas, Madrid: Experimental strategies to prevent and to treat (breast cancer) brain metastasis
• Clinic: Jens Huober, Canton Hospital St. Gallen: HER2 positive breast cancer – (r)evolution of treatment
• Industry: Javad Shahidi, Daiichi Sankyo, New Jersey: A new era for ADCs in oncology: Example from the HER2 space
  
  

18.00-18.30 – Break

18.30-21.00 – Apero, Dinner and poster session (4 best posters will be selected for a BBC award) 
Location: Restaurant “Zur Mägd”, St. Johanns-Vorstadt 29, 4056 Basel

Friday 19th of November 2021

Location: University Hospital, Pathology, “Oberer Hörsaal”, 1st floor, Schönbeinstrasse 40, 4031 Basel

8.30 – Session 3: Is it the beginning or the end of TBNC ?  (Chair: Simone Münst and Nicola Aceto)

• Basic: Walid Khaled, University of Cambridge: Differenciation dynamics of mammary epithelial cells during normal and malignant development
• Clinic: Christian Kurzeder, University Hospital Basel: Changing frameworks in treatment and sequencing using targeted and immunological interventions
• Industry: See Phan, Gilead Sciences Inc., Foster City: Development of Sacituzumab Govitecan, a NovelADC for TNBC

10.15 – Coffee break

10.45-11.15 – Round table discussion related to all Sessions (Chair: Gerhard Christofori and speakers from Sessions 1-3)

11.15-11.45 – Talk by patient advocate: Maria Katapodi, University of Basel: A patient’s perspective (Chair: Jane Shaw)

11.45-12.00 – BBC awards

12.00-13.00 – Keynote lecture: Matthew J Ellis, Baylor College of Medicine, Houston (Chair: M. Bentires-Alj)
The promises of proteogenomics-based diagnostics ?

13.00: Departure